ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
KOL Views Preview: AbbVie’s ABBV-951 works but will PD patients use it?
November 01, 2021ABBV-951 was expected to work better than oral levodopa/carbidopa and it did not disappoint in a Phase III trial for advanced Parkinson’s disease (PD). -
Analyst answers — What lies ahead for malignant melanoma?
December 05, 2018What changes do key opinion leaders (KOLs) see coming for malignant melanoma (MM) treatment? -
KOL Views: How does Opdivo’s stumble shift the balance of power in SCLC?
October 17, 2018KOL Views Imfinzi Keytruda Opdivo Tecentriq AstraZeneca BMS Merck & Co. Roche EMA FDA Lung Cancer Pulmonary/Respiratory Medicine Marketing & Sales Medical Affairs
Pharma Sources Insight January 2025
